亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

武漢昌達順科技有限公司  

醫藥原料及中間體,生物制品,營養補充劑等

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:王女士
  • 電話:027-87290258
  • 郵件:changdashun1010@163.com
  • QQ:497617324
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 苯磺酸左旋氨氯地平
苯磺酸左旋氨氯地平
單價 面議對比
詢價 暫無
發貨 湖北武漢市付款后3天內
過期 長期有效
更新 2014-03-12 17:38
 
詳細信息
 苯磺酸左旋氨氯地平 
【通用名稱】苯磺酸左旋氨氯地平 [國家醫保目錄乙類]
【英文名稱】Levamlodipine Besylate 
【化學名稱】(-)3-乙基-5-甲基-2-(2-氨乙氧甲基)-4-(2-氯苯基)-1,4-二氫-6-甲基-3,5-吡啶二羧酸酯苯磺酸鹽
【英文化學名】:(4S)-2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5
-pyridinedicarboxylic acid 3-ethyl 5-methyl ester benzenesulfonate。
【分子式】:C20H25N2O5Cl·C6H6O3S
【分子量】:567.1
【CAS號】:103129-82-4
【適應癥】:(1)高血壓:(單獨或與其他藥物合并使用)(2)心絞痛:尤其自發性心絞痛(單獨或與其他藥物合并使用)
 
©2025 武漢昌達順科技有限公司 版權所有   技術支持:化工網   訪問量:5753  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |